Patients with Diabetes Not at Highest Risk for Contrast-Induced Nephrotoxicity

Article

New study challenges common belief and finds patients with a history of renal disease, hypertension or heart disease were more likely to suffer renal insufficiency.

Patients with diabetes are not the highest risk group for developing contrast-induced nephrotoxicity as commonly believed, say researchers from Northwestern Memorial Hospital-Northwestern University in Chicago.

Instead, patients with a history of renal disease, hypertension or heart disease were more likely to suffer renal insufficiency, putting them at greater risk, according to their study, designed to find which group of patients at highest risk for contrast-induced nephrotoxicity. The results were presented at the American Roentgen Ray Society Annual Meeting this week in Vancouver, Canada.

Researchers evaluated 2,404 patients who underwent an estimated glomerular filtration rate (eGFR) test immediately before undergoing a CT examination. This allowed the researchers to see if the traditional risk factors accurately predicted reduced renal function.

“Patients with history of renal disease, hypertension, and heart disease had significantly higher odds of having abnormal eGFR,” said Vahid Yaghmai, MD, one of the study’s authors. This was not found in patients with a history of diabetes.

Yaghmai suggested eGFR be performed on the patients who indicate, via survey, that they are at high risk of such nephrotoxicity. “Measuring eGFR right before the CT scan can help us more accurately determine at-risk patients,” he said.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.